/PRNewswire/ -- Allergan, an AbbVie (NYSE: ABBV) company, today announced new data, including the full results from the Phase 3 GEMINI 1 clinical study, evaluating the efficacy, safety and tolerability...
Monday U.S. Economic Lookahead New Home Sales (June) Featured Earnings Tesla Inc. (NASDAQ:TSLA) ...
Investors will focus on revenue growth and other pipeline updates, when Tilray (TLRY) reports fiscal fourth-quarter results.
AbbVie (ABBV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved DALVANCE® (dalbavancin) for the treatment of acute bacterial skin and skin structure infections...
AbbVie (ABBV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
J&J (JNJ) and Novartis (NVS) announce Q2 results. FDA delays decisions on JAK inhibitor drugs of Lilly (LLY), AbbVie (ABBV) and Pfizer (PFE) for eczema indication.
The healthcare sector has been benefiting from COVID-19 vaccines or treatment with many more to come.
Roche's (RHHBY) performance in first-half 2021 was impressive on strong demand for new medicines and COVID-19 test kits. Impact of biosimilars continues to hurt sales.
Pfizer (PFE) partners with Biovac for manufacturing and distributing its COVID-19 vaccine in African Union. The FDA delays decision on Pfizer's regulatory filings for JAK inhibitors.
The report on Respiratory Syntactical Virus (RSV) provides the clients with a comprehensive analysis of crucial driving factors, consumer behavior, growth trends, product utilization, key player analysis,...
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
AbbVie (ABBV) is nearing a key resistance level. If that level is surpassed, a breakout is expected. AbbVie, Inc. ( ABBV ) is a research-based biopharmaceutical company, which engages in the development...
The FDA grants a Breakthrough Therapy designation to AbbVie's (ABBV) Venclexta in combination with azacitidine for treating adult patients with higher risk myelodysplastic syndrome.
The FDA notes deficiencies in the NDA seeking approval for Ardelyx's (ARDX) lead pipeline candidate, tenapanor, as a potential treatment for hyperphosphatemia.
J&J (JNJ) beats second-quarter 2021 estimates for both earnings and sales. It raises its financial expectations for the year. It forecasts $2.5 billion in 2021 sales of COVID-19 vaccine.
/PRNewswire/ --Â AbbVie (NYSE: ABBV) announced today that the U.S. Food and Drug Administration (FDA) granted a Breakthrough Therapy Designation (BTD) to venetoclax (VENCLEXTA) in combination with azacitidine...
/PRNewswire/ --Â Allergan, an AbbVie (NYSE: ABBV) company, today announced that it will present new data from its leading portfolio of eye care medicines at the 2021 ASCRS (American Society for Cataract...
In the latest trading session, AbbVie (ABBV) closed at $115.42, marking a -1.77% move from the previous day.
